NCT05418465

Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy

A Prospective, Open, Multicenter, Clinical Study of Huangqi Guizhi Wuwu Decoction in Treating Diabetic Nephropathy (Stage CKD2-4)

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: The First Affiliated Hospital of Dalian Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, open, multicenter clinical trial.The objective of this study is to evaluate the efficacy and safety of Huangqi Guizhi Wuwu Decoction in patients with CKD stage 2-4 diabetic nephropathy.

Detailed description

The incidence rate of chronic kidney disease is 10.8% in China. The incidence rate of diabetic nephropathy has increased year by year, and now it has become the first cause of uremia. Therefore, the treatment of diabetic nephropathy can delay the progression of renal function and is of great value and significance in reducing uremia. Huangqi Guizhi Wuwu decoction is a traditional Chinese medicine decoction. Previous studies have shown that it is effective in the treatment of diabetic nephropathy. In this study, there were 2 hospitals participating in. We planned to enroll 100 participants, who will be divided into the Huangqi Guizhi Wuwu decoction group (experimental group) and the Dapagliflozin group (control group). All participants will take medication for 12 weeks, and investigators will follow up participates at weeks 0, 2,4, 6, 8,12.

Conditions

• Diabetic Nephropathies

Interventions

Type	Name	Description
DRUG	Huangqi Guizhi Wuwu decoction	Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.
DRUG	Dapagliflozin	Dapagliflozin, 10mg at a time, once a day. Oral administration.

Timeline

• Start date: 2022-01-26
• Primary completion: 2022-12-31
• Completion: 2022-12-31
• First posted: 2022-06-14
• Last updated: 2022-06-14

Locations

1 site across 1 country: China